236 related articles for article (PubMed ID: 37828600)
1. The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review and meta-analysis.
Yang CL; Huang JP; Tan YC; Wang TT; Zhang H; Qu Y
BMC Pharmacol Toxicol; 2023 Oct; 24(1):52. PubMed ID: 37828600
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of botulinum toxin for treating sialorrhea: A systematic review and meta-analysis.
Yu YC; Chung CC; Tu YK; Hong CT; Chen KH; Tam KW; Kuan YC
Eur J Neurol; 2022 Jan; 29(1):69-80. PubMed ID: 34449931
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
Guidubaldi A; Fasano A; Ialongo T; Piano C; Pompili M; Mascianà R; Siciliani L; Sabatelli M; Bentivoglio AR
Mov Disord; 2011 Feb; 26(2):313-9. PubMed ID: 21259343
[TBL] [Abstract][Full Text] [Related]
4. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E; Ellis C; Brassington R; Sathasivam S; Young CA
Cochrane Database Syst Rev; 2022 May; 5(5):CD006981. PubMed ID: 35593746
[TBL] [Abstract][Full Text] [Related]
5. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
Egevad G; Petkova VY; Vilholm OJ
J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
[TBL] [Abstract][Full Text] [Related]
6. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Ondo WG; Hunter C; Moore W
Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
[TBL] [Abstract][Full Text] [Related]
7. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the pharmacological treatments for sialorrhea in patients with Parkinson's disease: a systematic review and network meta-analysis.
Santos Junior LC; Santos JR; Reis A; Faria-E-Silva AL; Leal PC
Clin Oral Investig; 2023 Jun; 27(6):2449-2463. PubMed ID: 37036514
[TBL] [Abstract][Full Text] [Related]
9. Onabotulinum Toxin A (BoNT-A) for Drooling in Children: A Systematic Review and Meta-Analysis.
Oad H; Maltezeanu A; da Silva SD; Daniel SJ
Laryngoscope; 2024 Jul; 134(7):3012-3017. PubMed ID: 38294288
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins.
Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G
Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
J Neurol; 2009 Apr; 256(4):563-7. PubMed ID: 19401804
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
[TBL] [Abstract][Full Text] [Related]
14. Oral health effects of botulinum toxin treatment for drooling: a systematic review.
Corrêa LB; Basso MB; Sousa-Pinto B; Coelho Leal S
Med Oral Patol Oral Cir Bucal; 2021 Mar; 26(2):e172-e180. PubMed ID: 33340083
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial.
Isaacson SH; Ondo W; Jackson CE; Trosch RM; Molho E; Pagan F; Lew M; Dashtipour K; Clinch T; Espay AJ;
JAMA Neurol; 2020 Apr; 77(4):461-469. PubMed ID: 31930364
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.
Barbero P; Busso M; Tinivella M; Artusi CA; De Mercanti S; Cucci A; Veltri A; Avagnina P; Calvo A; Chio' A; Durelli L; Clerico M
J Neurol; 2015 Dec; 262(12):2662-7. PubMed ID: 26410746
[TBL] [Abstract][Full Text] [Related]
17. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
[TBL] [Abstract][Full Text] [Related]
18. Comparing the evidence for botulinum neurotoxin injections in paediatric anterior drooling: a scoping review.
Orriëns LB; van Hulst K; van der Burg JJW; van den Hoogen FJA; Willemsen MAAP; Erasmus CE
Eur J Pediatr; 2024 Jan; 183(1):83-93. PubMed ID: 37924348
[TBL] [Abstract][Full Text] [Related]
19. Botulinum Toxin for the Management of Parkinson's Disease: A Systematic Review.
Slouha E; Ibrahim F; Esposito S; Mursuli O; Rezazadah A; Clunes LA; Kollias TF
Cureus; 2024 Jan; 16(1):e53309. PubMed ID: 38435899
[TBL] [Abstract][Full Text] [Related]
20. RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials.
Dashtipour K; Bhidayasiri R; Chen JJ; Jabbari B; Lew M; Torres-Russotto D
J Clin Mov Disord; 2017; 4():9. PubMed ID: 28593050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
